Relay Therapeutics, Inc.
RLAY
Classificação em ações
#4085
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Preço da ação
$18.21
Valor de mercado
$3.99B
Variação (1 dia)
6.55%
Variação (1 ano)
155.04%
País
US
Negociar Relay Therapeutics, Inc. (RLAY)
Categoria
Healthcare
Lucros da Relay Therapeutics, Inc. (RLAY)
Lucros em Jun 2026 TTM: $-286.04M
De acordo com os últimos relatórios financeiros da Relay Therapeutics, Inc., os ganhos atuais da empresa são de $-286.04M. Em 2023, a empresa teve ganhos de $-341.97M, uma diminuição em relação a aos ganhos de 2022, que foram de $-290.51M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Relay Therapeutics, Inc. de 2018 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-286.04M | -15.30% |
| 2024 | $-337.71M | -1.25% |
| 2023 | $-341.97M | 17.72% |
| 2022 | $-290.51M | -20.16% |
| 2021 | $-363.87M | 594.25% |
| 2020 | $-52.41M | -30.40% |
| 2019 | $-75.31M | 54.36% |
| 2018 | $-48.79M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -1,944.13% |
US
|
|
| $-3.09B | 979.23% |
US
|
|
| $-4.02B | 1,304.08% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -781.96% |
NL
|
